MONTPELLIER, France, July 16, 2019 /PRNewswire/ -- SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach designed to improve cancer surgery and clinical outcomes for patients, today announces that the first surgical procedure was carried out in a pivotal Phase 3 clinical

FLORENCE, Italy, July 16, 2019 /PRNewswire/ -- Two days dedicated to sport  and the greater values of Fair Play. Last July the city of Florence hosted the XXIII^ edition of the International Fair Play Menarini Award: the annual event which celebrates those sporting champions who have stood out in the world of sports for t

UPPSALA, Sweden, July 16, 2019 /PRNewswire/ -- Second quarter April – June 2019Net sales amounted to 282.1 MSEK (236.1), which is an increase by 19.5 percent compared to the corresponding quarter last year. At comparable exchange rates[1] and adjusted for acquisitions, sales increased by 5.8 percent.

BARCELONA, Spain, July 16, 2019 /PRNewswire/ -- The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial for the treatment of Alzheimer's at the Alzheimer's Association International Conference (AAIC) 2019 in Los Angeles

TOKYO and LONDON, July 16, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces that it has entered into a multi-target research collaboration and license agreement with Genentech, a member of the Roche Group, to discover and develop novel medicines (new small molecules and/or biologics) that modulate G protein-coupled receptor (GPCR

CAMBRIDGE, Massachusetts and LUND, Sweden, July 16, 2019 /PRNewswire/ -- Ra Pharmaceuticals, Inc. (Nasdaq: RARX) and Camurus AB (Nasdaq STO: CAMX) today announced an exclusive worldwide license agreement for the use of Camurus's proprietary FluidCrystal® (FC) technology to develop, manufacture, and commercialize a long-acting formulat

EAST HANOVER, N.J., July 16, 2019 /PRNewswire/ -- Novartis today announced the US Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) and has granted Priority Review for its investigational sickle cell medicine crizanlizumab (SEG101). If FDA-approved, crizanlizumab is expected to represent the first monoclonal antibody targeting

WINDSOR LOCKS, Conn. and EASTHAMPTON, Mass., July 16, 2019 /PRNewswire/ -- S.M.A.R.T.'s conference on August 17 - 18, 2019 in Connecticut is less than a month away.

BERKELEY, Calif., July 16, 2019 /PRNewswire/ -- The U.S. Patent and Trademark Office (USPTO) has awarded a new patent to the University of California (UC), University of Vienna, and Dr. Emmanuelle Charpentier covering methods of producing a genetically modified cell through the in

AQUEBOGUE, N.Y., July 15, 2019 /PRNewswire/ -- Altaire Pharmaceuticals, Inc., announces today that it is voluntarily recalling the Prescription (RX) and Over-the-Counter (OTC) drug products and lots, within expiry, sold by OCuSOFT during the time period as indicated in the tables below. As a precautionary measure, Altaire is voluntarily initiating the recall due to management conc